0000 GMT - Sonic Healthcare may have reiterated its earnings guidance alongside its 1H result today, but Barrenjoey thinks good news may be on the cards from the pathology services provider. Sonic expects FY 2025 Ebitda of A$1.70 billion-A$1.75 billion when currency swings are stripped out. At the midpoint of that range, guidance implies a 52% skew towards 2H, analyst Anshul Baruah says. That is lower than the skew in FY 2019, before Sonic's results got a boost from Covid-19 testing revenues. It suggests Sonic is more likely to achieve the upper end of its Ebitda guidance, Barrenjoey says. Sonic is down 2.3% today. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
February 19, 2025 19:00 ET (00:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。